Ace revisited: a new target for structure-based drug design. - Test2 - elhamkhani - TriplyDB

Ace revisited: a new target for structure-based drug design.

Ace revisited: a new target for structure-based drug design.

http://www.wikidata.org/entity/Q34282839

about

Structural basis of peptide recognition by the angiotensin-1 converting enzyme homologue AnCE from Drosophila melanogaster A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme Natural Inhibitors of Snake Venom Metalloendopeptidases: History and Current Challenges The Effects of Angiotensin Converting Enzyme Inhibitors (ACE-I) on Human N-Acetyl-Seryl-Aspartyl-Lysyl-Proline (Ac-SDKP) Levels: A Systematic Review and Meta-Analysis N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes Characterization of domain-selective inhibitor binding in angiotensin-converting enzyme using a novel derivative of lisinopril Novel mechanism of inhibition of human angiotensin-I-converting enzyme (ACE) by a highly specific phosphinic tripeptide Structural characterization of angiotensin I-converting enzyme in complex with a selenium analogue of captopril Molecular recognition and regulation of human angiotensin-I converting enzyme (ACE) activity by natural inhibitory peptides Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors Crystal structures of highly specific phosphinic tripeptide enantiomers in complex with the angiotensin-I converting enzyme Molecular and Thermodynamic Mechanisms of the Chloride-dependent Human Angiotensin-I-converting Enzyme (ACE)Mining the unknown: a systems approach to metabolite identification combining genetic and metabolic information.The toxicity of angiotensin converting enzyme inhibitors to larvae of the disease vectors Aedes aegypti and Anopheles gambiae Dual colour, microarray-based, analysis of 10,000 protease substrates.Identification and characterisation of the angiotensin converting enzyme-3 (ACE3) gene: a novel mammalian homologue of ACE.ACE for all - a molecular perspective Peptides and peptidomimetics as immunomodulators.Novel ketomethylene inhibitors of angiotensin I-converting enzyme (ACE): inhibition and molecular modelling.Extracellular proteases as targets for drug development Inhibitor and substrate binding by angiotensin-converting enzyme: quantum mechanical/molecular mechanical molecular dynamics studies.Structure-activity relationship of conformationally constrained peptidomimetics for antiproliferative activity in HER2-overexpressing breast cancer cell lines.Increased angiotensin II-induced hypertension and inflammatory cytokines in mice lacking angiotensin-converting enzyme N domain activity.Structure of testis ACE glycosylation mutants and evidence for conserved domain movement.Targeting proteases in cardiovascular diseases by mass spectrometry-based proteomics.Structural basis of Ac-SDKP hydrolysis by Angiotensin-I converting enzyme.Insights into the Hypertensive Effects of Tityus serrulatus Scorpion Venom: Purification of an Angiotensin-Converting Enzyme-Like Peptidase Angiotensin Converting Enzyme Regulates Cell Proliferation and Migration.ACE inhibition prevents diastolic Ca2+ overload and loss of myofilament Ca2+ sensitivity after myocardial infarction.Angiotensin-converting enzyme inhibitor-related angioedema: how to deal with it.Identification of ACE pharmacophore in the phosphonopeptide metabolite K-26.Angiotensin-converting enzyme 2 and the kidney.Kinetic and structural characterization of amyloid-β peptide hydrolysis by human angiotensin-1-converting enzyme.Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2.Inhibition of renin and the (pro)renin receptor system.The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis.The influence of angiotensin converting enzyme mutations on the kinetics and dynamics of N-domain selective inhibition.Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells.Isolation and biochemical characterization of bradykinin-potentiating peptides from Bitis gabonica rhinoceros.A new high-resolution crystal structure of the Drosophila melanogaster angiotensin converting enzyme homologue, AnCE.

P2860

Q24301320-2CF4772D-05F4-46E8-AE68-7BA4A91368B9 Q24306614-3A1DB62D-8698-4DD1-80C0-FF183B5FEE3C Q26738414-D0B84ED3-16E1-4D2B-A5F2-94C2C10A331C Q26776514-E344D1FC-1118-4A29-A712-207F82838618 Q27008887-844438F4-DD0B-4A4D-B9B8-D59BFD95C2D6 Q27660250-5A794CB9-E9A9-494E-A205-1AE0AF5C38A6 Q27667064-553EDD4A-032A-4BBB-A9AF-4A38604BFA69 Q27671388-6D275F4C-FE36-4DF2-832B-D0DD98CCA778 Q27674442-F4279806-7932-4969-8C23-C09D8F34461E Q27679900-29D9340E-0C86-4F2C-9C69-C91506D0B2C3 Q27680712-29B9F6AF-9757-4179-92E2-AF9FE9A78D8A Q27680735-3418BF68-93ED-408B-9624-6A8374764F3D Q28484480-4ADA8A93-3CE0-4FA6-891E-089E44AA7D77 Q29198329-A8D1D503-3D44-45AB-AF88-8239B0A4DB80 Q33258557-3AF6E8DD-5F04-451B-B89B-210739BE24DD Q33289135-D093516D-5487-4F81-8F67-D209E15D9A4C Q34195870-BF20A578-F4D6-4EFA-8FB7-C068667F4AF2 Q34359984-B0304445-2F1F-4E68-97BA-353274429CC0 Q34512406-B67EBE76-5A71-4856-9258-105AFBBE7385 Q35116202-9854C5EC-7DA5-4233-B71B-DBE5D99AFCC2 Q35167293-9C7190C5-7D8B-463F-8A13-16682AC21FB6 Q35185574-BC644115-B486-496A-ABCE-0FFE5BE0581B Q35696855-C6525BC4-AA72-485B-B57F-102B56A71B43 Q35843917-FED00DDB-5F83-4424-A785-0996CD4BCF0F Q35897743-D8A996BD-6CE5-42E0-AB9B-45EC08D49625 Q36099917-B1427248-D0FE-4A0E-BFD7-177F480C9520 Q36203920-61F85221-FDDC-4CA5-ACE8-F98DD1351DAD Q36227957-E089A17B-B2E7-4181-A038-8886D4795AC4 Q36320507-CCCB9A24-6B1C-474B-9A1A-CC26405C3E9B Q36565040-BF4EF931-F9D0-4619-97F8-1271B75C0263 Q36725891-05779CC0-DD1D-4221-87A0-57D89A7F2D58 Q37068454-733B4AB2-3065-42D8-84B3-F496038CF573 Q37107046-7B23ECB7-D751-4638-B979-8882C489D4FA Q37264506-3F1510D9-93F2-4185-A4D4-A786370538DC Q38024862-F0BC5F18-D687-4F3B-BBF6-DB1D277CD0FD Q38224257-79A3B5F0-F528-47E5-B67F-DB14433C7EAC Q38820520-280CC852-AFDA-4F33-8893-F1079FB70CCD Q40373012-A6F152A3-7A2B-42FD-B9A7-25E5318C26FE Q41036113-CDD3D856-7E10-4524-94F5-B85E345D54B7 Q41906309-94E139BA-3A44-4DCC-9FCB-64F40A0EC175

P2860

Ace revisited: a new target for structure-based drug design.

http://www.wikidata.org/entity/Q34282839

description

2003 nî lūn-bûn

@nan

2003 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Ace revisited: a new target for structure-based drug design.

@ast

Ace revisited: a new target for structure-based drug design.

@en

Ace revisited: a new target for structure-based drug design.

@nl

type

label

Ace revisited: a new target for structure-based drug design.

@ast

Ace revisited: a new target for structure-based drug design.

@en

Ace revisited: a new target for structure-based drug design.

@nl

prefLabel

Ace revisited: a new target for structure-based drug design.

@ast

Ace revisited: a new target for structure-based drug design.

@en

Ace revisited: a new target for structure-based drug design.

@nl

P1433

Q34282839-8AA6B6DB-DF5B-411A-91FC-ABFBBAB1790A

P1476

Q34282839-725FDA29-D7FF-406B-939D-326C2FB31013

P2093

Q34282839-17EB0889-0170-4ED9-8156-D4ACA65321A6

Q34282839-C8E30545-6F50-47F7-AE0A-DB54E42C89B0

Q34282839-ECCF30F5-1A6A-4D8C-AA63-A747846184C3

P2860

Q34282839-052D3C4A-4BC6-4F47-8712-15FAB6CB9FE8

Q34282839-10639558-215E-4D61-B088-23C077DBC067

Q34282839-1531CBC1-8615-43D8-9941-E6897C687E49

Q34282839-184045F8-BE32-4B69-9A2B-1F627BB268AA

Q34282839-196E355E-6080-416F-8D2A-8DD599C45063

Q34282839-1A7964FA-F99F-452E-9207-44341B8E5F4A

Q34282839-257147E9-69C9-4B5C-920F-7D399E147F7F

Q34282839-30444DE5-EAE0-48B1-AC55-F0BCAEC8858A

Q34282839-33E824A3-FCDA-47D2-B75C-5C42AF392E9B

Q34282839-3FC2771B-21C1-4C44-8EE5-68702A57B366

P2888

Q34282839-5562D995-C787-4558-B8F0-5CDD9B6C2927

P304

Q34282839-8F16C2EB-18F1-4825-B363-D9A7251C01B4

P31

Q34282839-31CB9C65-07BA-49F1-9C91-9C209D9F37B4

Q34282839-86d1b6f8-ce92-4bec-955c-c60c1d5ac446

P356

Q34282839-80C1676C-0524-4995-801E-6F002442ECE2

P433

Q34282839-49894F3E-2FDC-4C38-B4D6-6493748E4554

P478

Q34282839-35CF5FFA-5252-4C3A-AB13-1E948ECB8F34

P50

Q34282839-BFB573C9-3ABB-4BE3-A43E-A2075D2C9821

P577

Q34282839-8A20E050-C93A-445D-9618-6B4BB6C44DBA

P698

Q34282839-597AACD9-2023-4AFB-8904-ACF8DC7DBD36

P356

P1433

Nature Reviews Drug Discovery

P1476

Ace revisited: a new target for structure-based drug design

@en

P2093

Edward D Sturrock

http://www.w3.org/2001/XMLSchema#string

James F Riordan

http://www.w3.org/2001/XMLSchema#string

Mario R W Ehlers

http://www.w3.org/2001/XMLSchema#string

P2860

Crystal structure of the human angiotensin-converting enzyme-lisinopril complex

The hemoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme

Structure of neurolysin reveals a deep channel that limits substrate access

Crystal structure of a novel carboxypeptidase from the hyperthermophilic archaeon Pyrococcus furiosus

Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril

High-throughput crystallography for lead discovery in drug design.

Functional conservation of the active sites of human and Drosophila angiotensin I-converting enzyme.

RXP 407, a phosphinic peptide, is a potent inhibitor of angiotensin I converting enzyme able to differentiate between its two active sites.

Shedding of somatic angiotensin-converting enzyme (ACE) is inefficient compared with testis ACE despite cleavage at identical stalk sites

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II.

P2888

P304

891-902

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRD1227

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

K. Ravi Acharya

P577

2003-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

14668810

http://www.w3.org/2001/XMLSchema#string